risankizumab
abbvie
['ibd', 'marker ']
practical conclusion: if the patient is not very sick, can give il-23 inhibitors some time to work; however, i suspect these patients have an early (bio)marker of response even if clinically they don't qualify as "responders" per trial criteria #uegweek22 #ibd
Swedish physician specializing in the treatment of Crohn's disease and Ulcerative Colitis. Views - my own.